Literature DB >> 33634351

Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points.

Maura Rossi1, Alessio Gambino2, Marco Cabras3, Manuela Alessio4, Vittorio Fusco1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33634351     DOI： 10.1007/s00520-021-06100-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  6 in total

1.  Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?

Authors:  Vittorio Fusco; Alberto Bedogni; Alfredo Addeo; Giuseppina Campisi
Journal:  Support Care Cancer       Date:  2016-03-09       Impact factor: 3.603

2.  Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.

Authors:  Tomoko Higuchi; Yoshihiko Soga; Misato Muro; Makoto Kajizono; Yoshihisa Kitamura; Toshiaki Sendo; Akira Sasaki
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2018-03-06

3.  Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.

Authors:  Tine Loyson; Thomas Van Cann; Patrick Schöffski; Paul M Clement; Oliver Bechter; Isabel Spriet; Ruxandra Coropciuc; Constantinus Politis; Raf O Vandeweyer; Joseph Schoenaers; Herlinde Dumez; Patrick Berteloot; Patrick Neven; Kristiaan Nackaerts; Feng J S H Woei-A-Jin; Kevin Punie; Hans Wildiers; Benoit Beuselinck
Journal:  Acta Clin Belg       Date:  2017-07-10       Impact factor: 1.264

4.  Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.

Authors:  Noam Yarom; Towy Sorel Lazarovici; Sara Whitefield; Tal Weissman; Oshri Wasserzug; Ran Yahalom
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2017-09-28

5.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

6.  Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Authors:  Alison T Stopeck; Karim Fizazi; Jean-Jacques Body; Janet E Brown; Michael Carducci; Ingo Diel; Yasuhiro Fujiwara; Miguel Martín; Alexander Paterson; Katia Tonkin; Neal Shore; Paul Sieber; Frank Kueppers; Lawrence Karsh; Denise Yardley; Huei Wang; Tapan Maniar; Jorge Arellano; Ada Braun
Journal:  Support Care Cancer       Date:  2015-09-03       Impact factor: 3.603
  6 in total
  2 in total

1.  One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Vittorio Fusco; Giuseppina Campisi; Alberto Bedogni
Journal:  Support Care Cancer       Date:  2022-03-21       Impact factor: 3.359

2.  Fluorescent risedronate analogue 800CW-pRIS improves tooth extraction-associated abnormal wound healing in zoledronate-treated mice.

Authors:  Hiroko Okawa; Takeru Kondo; Akishige Hokugo; Philip Cherian; Oskar Sundberg; Jesus J Campagna; Boris A Kashemirov; Varghese John; Shuting Sun; Frank H Ebetino; Charles E McKenna; Ichiro Nishimura
Journal:  Commun Med (Lond)       Date:  2022-09-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.